Skip to main content
CONTEC MEDICAL SYSTEMS CO., LTD. logo

CONTEC MEDICAL SYSTEMS CO., LTD. — Investor Relations & Filings

Ticker · 300869 ISIN · CNE1000047F0 LEI · 6556007SL3V6YKCWVA55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 789 across all filing types
Latest filing 2020-07-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300869

About CONTEC MEDICAL SYSTEMS CO., LTD.

https://www.contecmed.com.cn

CONTEC Medical Systems Co., Ltd. focuses on the research, development, manufacturing, and distribution of medical electronic instruments. The product portfolio encompasses a wide range of diagnostic and monitoring solutions, including pulse oximeters, blood pressure monitors, electrocardiographs, ultrasound equipment, and multi-parameter patient monitors. Additionally, the company provides specialized devices such as fetal monitors, sleep apnea screening systems, and biochemical analyzers. By leveraging integrated research and large-scale production facilities, the organization delivers medical technology designed for clinical, hospital, and home healthcare environments. The company emphasizes technical innovation and adheres to international quality standards to ensure the precision and reliability of its medical hardware and software solutions.

Recent filings

Filing Released Lang Actions
首次公开发行股票并在创业板上市招股意向书
Capital/Financing Update Classification · 95% confidence The document is a detailed "招股意向书" (Prospectus or Offering Intention Document) for an initial public offering (IPO) of 康泰医学系统（秦皇岛）股份有限公司 on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive information about the offering, risk factors, company background, financial data, governance, and management analysis. The document is lengthy (15,000 characters) and contains substantive financial data, risk disclosures, and company operational details. It is not a simple announcement or a brief summary but a comprehensive offering prospectus. This type of document corresponds to a capital raising and financing activity, specifically an IPO prospectus, which fits best under the category "Capital/Financing Update (CAP)" as it relates to fundraising and issuance of new shares. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or announcement. Therefore, the correct classification is CAP with high confidence.
2020-07-30 Chinese
非经常性损益明细表的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report by Deloitte regarding the non-recurring profit and loss details of Kangtai Medical System (Qinhuangdao) Co., Ltd. for the years 2017, 2018, and 2019. It includes audited financial data and references an audit report issued with an unqualified opinion. The document is a standalone audit-related report focusing on a specific financial detail (non-recurring profit and loss) and is issued by an accounting firm. It is not a full annual report (10-K), nor is it a general announcement or certification. The document length is 3632 characters, which is relatively short but contains substantive audited financial data and explanations. Therefore, it fits best under the category of Audit Report / Information (AR).
2020-07-30 Chinese
监事对招股说明书的确认意见
Regulatory Filings Classification · 95% confidence The document is a confirmation opinion from the supervisory board regarding the prospectus for the company's initial public offering (IPO) and listing on the Growth Enterprise Market. It is a certification statement confirming the accuracy and completeness of the prospectus, signed by the supervisors. The document is very short (742 characters) and contains no financial data or detailed report content. It is essentially an attestation related to a regulatory filing (the prospectus). According to the Certification Rule, such officer certifications or confirmations should be classified as Regulatory Filings (RNS), not as the prospectus or IPO document itself.
2020-07-30 Chinese
申万宏源证券承销保荐有限责任公司关于公司首次公开发行股票并在创业板上市之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to 康泰医学系统（秦皇岛）股份有限公司's initial public offering (IPO) and listing on the ChiNext board. It is issued by the underwriting and sponsoring institution 申万宏源证券承销保荐有限责任公司. The content includes detailed descriptions of the underwriting institution, the IPO process, due diligence, legal compliance, risk disclosures, and internal review procedures. This document is a formal sponsorship letter for the IPO, which is a regulatory filing related to the issuance and underwriting process rather than a financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, nor a Management Report. It is also not a simple announcement or a proxy statement. Given the nature of the document as a formal underwriting and sponsorship letter for a capital market transaction (IPO), it fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is a full report, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2020-07-30 Chinese
申万宏源证券承销保荐有限责任公司关于公司首次公开发行股票并在创业板上市之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to a "Listing Sponsorship Letter" or "Sponsorship Document" related to the company's initial public offering (IPO) and listing on the Growth Enterprise Market (创业板). It is issued by the underwriting and sponsoring securities company for the IPO of 康泰医学系统（秦皇岛）股份有限公司. The content includes detailed information about the issuer, core technologies, business overview, financial data, risk factors, and specifics about the stock issuance. This type of document is a formal sponsorship report required for IPOs in China, which is distinct from an annual report or earnings release. It is not a simple announcement or a brief summary but a comprehensive document supporting the IPO process. Given the nature of the document as a sponsorship report for an IPO, it falls under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities including IPOs.
2020-07-30 Chinese
北京市中伦律师事务所关于公司首次公开发行股票并在创业板上市的补充法律意见书（八）
Audit Report / Information Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding the initial public offering (IPO) of 康泰医学系统（秦皇岛）股份有限公司 on the ChiNext board. It is titled as a "Supplementary Legal Opinion Letter (Eight)" and discusses ongoing patent litigation and related legal matters. The document includes extensive legal analysis, references to prior legal opinions, and detailed descriptions of lawsuits and their impact on the company. It is not a financial report, earnings release, or management discussion, nor is it a simple announcement or certification. The document is a standalone legal report related to audit and regulatory compliance matters concerning the IPO process and legal risks. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document is substantive and lengthy (15,000 characters), not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). H1 2020
2020-07-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.